Armodafinil ( DrugBank: Armodafinil )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1
13多発性硬化症/視神経脊髄炎1
84サルコイドーシス1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01256905
(ClinicalTrials.gov)
January 1, 20118/12/2010Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy BodiesAttention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy BodiesParkinsons Disease;Lewy Bodies DiseaseDrug: ArmodafinilNYU Langone HealthCephalonWithdrawn50 Years80 YearsAll0N/AUnited States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00981084
(ClinicalTrials.gov)
September 200918/9/2009Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover StudyMultiple SclerosisDrug: armodafinilUniversity of Missouri, Kansas CityUniversity of KansasCompleted18 Years60 YearsAll33Phase 2/Phase 3United States

84. サルコイドーシス


臨床試験数 : 149 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00555347
(ClinicalTrials.gov)
October 20077/11/2007Use of Armodafinil for Fatigue in SarcoidosisUse of Armodafinil (R-modafinil) for Fatigue in SarcoidosisSarcoidosis;Fatigue;SleepinessDrug: Armodafinil;Drug: PlaceboUniversity of CincinnatiCephalonCompleted18 YearsN/ABoth20Phase 2/Phase 3United States